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Abstract
Type 1 diabetes (T1D) is characterized by the loss of insulin-producing b-cells in the pancreas. T1D can be treated using
cadaveric islet transplantation, but this therapy is severely limited by a lack of pancreas donors. To develop an alternative cell
source for transplantation therapy, we carried out the epigenetic characterization in nine different adult mouse tissues and
identified visceral adipose-derived progenitors as a candidate cell population. Chromatin conformation, assessed using chromatin
immunoprecipitation (ChIP) sequencing and validated by ChIP-polymerase chain reaction (PCR) at key endocrine pancreatic
gene promoters, revealed similarities between visceral fat and endocrine pancreas. Multiple techniques involving quantitative
PCR, in-situ PCR, confocal microscopy, and flow cytometry confirmed the presence of measurable (2–1000-fold over detectable
limits) pancreatic gene transcripts and mesenchymal progenitor cell markers (CD73, CD90 and CD105; >98%) in visceral
adipose tissue-derived mesenchymal cells (AMCs). The differentiation potential of AMCs was explored in transgenic reporter
mice expressing green fluorescent protein (GFP) under the regulation of the Pdx1 (pancreatic and duodenal homeobox-1) gene
promoter. GFP expression was measured as an index of Pdx1 promoter activity to optimize culture conditions for endocrine
pancreatic differentiation. Differentiated AMCs demonstrated their capacity to induce pancreatic endocrine genes as evidenced
by increased GFP expression and validated using TaqMan real-time PCR (at least 2–200-fold relative to undifferentiated AMCs).
Human AMCs differentiated using optimized protocols continued to produce insulin following transplantation in NOD/SCID
mice. Our studies provide a systematic analysis of potential islet progenitor populations using genome-wide profiling studies and
characterize visceral adipose-derived cells for replacement therapy in diabetes.
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Introduction
Diabetes mellitus is a chronic metabolic disease defined by
an inability to regulate circulating glucose concentrations.
Type 1 diabetes (T1D) is characterized by the selective
autoimmune-mediated destruction of pancreatic islet b-
cells. This pathological loss of b-cell mass, results in a
failure to produce insulin, in response to changes in blood
glucose concentrations. If untreated, the resultant hypergly-
cemia can lead to serious microvascular (retinopathy,
nephropathy, and neuropathy) and/or macrovascular com-
plications (coronary/peripheral artery disease and stroke).
Individuals with T1D require stringent monitoring of blood
glucose levels and treatment with exogenous insulin admi-
nistered through regular injections or through continuous
monitoring insulin pumps1.
Current management plans for T1D patients are generally
effective and can achieve good glycemic control with inten-
sive insulin therapy. However, these pharmacological
approaches, while effective, fail to completely recapitulate
the true biology of a healthy pancreas. This can be achieved
either through total pancreas transplantation or through islet
transplantation, so as to replace the dying/lost insulin-
producing b-cells. In 2000, Shapiro et al.2 first described a
procedure involving a steroid-free immunosuppressive regi-
men for the transplantation of allogeneic islets isolated from
the human cadaveric pancreas (the Edmonton protocol). This
study demonstrated that for patients with T1D, islet trans-
plantation can result in insulin independence with excellent
metabolic control when glucocorticoid-free immunosup-
pression is combined with the infusion of an adequate islet
mass. Unfortunately, this technique is limited by low num-
bers of cadaveric donors and the restricted yield of viable
cells for transplantation3. Therefore, many research groups
across the world are in search of alternative cell sources that
have the potential to differentiate into insulin-producing
cells for transplantation4.
Cells isolated from pancreatic tissues (endocrine, acinar
or ductal) or other endodermal sources have potential as
alternative sources for the generation of insulin-producing
cells. There is now a growing body of evidence to suggest
that it is possible to induce the trans-differentiation of endo-
dermal cells such as hepatocytes5–7, intra-/extra-hepatic bili-
ary epithelial cells8 and gallbladder epithelium9,10 to express
markers characteristic of the pancreatic lineage. Adipose
tissue has been one of the more widely explored sources of
tissues for assessing its potential to differentiate into insulin-
producing cells11–16. However, adipocytes are located in
distinct depots, which demonstrate significantly different
gene expression patterns17–19. Thus, progenitor/precursor
cells residing in the visceral or the subcutaneous fat depots
possess inherent and specific metabolic characteristics that
may guide the differentiation of progenitor cells derived
from such tissues. We theorize that epigenetic mechanisms
that dictate the chromatin conformation of DNA in adipose
tissue depots govern their cell fate during differentiation and
that understanding the epigenetic conformation (histone
modifications) in adipose tissue depots would aid in
assessing their differentiation potential to an endocrine
pancreatic fate.
Genetic and epigenetic mechanisms are thought to repre-
sent the primary control for cellular differentiation and
developmental biology. Epigenetic mechanisms principally
involve histone post-translational modifications and DNA
methylation20, but can also include noncoding RNAs21–23
and nuclear dynamics24,25. Combining chromatin structure
analysis using chromatin immunoprecipitation (ChIP) with
comprehensive sequencing provides genome-wide measure-
ments of chromatin structure, which can be integrated with
RNA transcriptome sequencing to provide a detailed analy-
sis of transcriptional networks in a given tissue. Here we
show that the profiling of histone modifications and gene
expression in multiple mouse tissues using ChIP-seq and
RNA-seq platforms identified visceral adipose tissue as a
source of progenitor cells that are epigenetically poised to
differentiate into an endocrine pancreatic lineage. We pres-
ent the characterization and differentiation of these cells
using a variety of imaging and molecular techniques.
Finally, we present data on their potential to produce insulin,
following transplantation in mice.
Materials and Methods
All animal and human work presented herein was approved
by specific Animal and Human Ethics Committees at the St.
Vincent’s Hospital, Melbourne, Australia. Animals were
handled in accordance with the National Health and Medical
Research Council (NHMRC) guidelines for the care and
maintenance of experimental animals.
Chromatin Immunoprecipitation Analysis
and Sequencing
Healthy 12-week-old male C57/Bl-6 mice were euthanized
and organs (skin, peritoneum, heart, visceral adipose, subcu-
taneous adipose, liver, stomach, brain, and pancreas) were
harvested immediately. Organs were maintained in chilled
low glucose Dulbecco’s modified Eagle’s medium (DMEM;
Gibco, Thermo Fisher Scientific, Waltham, MA, USA) con-
taining 5 mM glucose and 2 mM L-glutamine (GlutaMAX-1;
Gibco, Thermo Fisher Scientific) on ice. Single cell
suspensions were generated using mechanical and enzymatic
dissociation. Pelleted cells were collected for chromatin
immunoprecipitation using a protocol described previously26.
Briefly, cells were cross-linked using 1% formaldehyde
(Sigma, St. Louis, MO, USA) and DNA sheared using a Bior-
uptor to generate fragments of 200–500 base pairs (bp)
required for ChIP. Chromatin was immunoprecipitated using
2 mg of specific antibodies for H3K4 trimethyl, H3K9 tri-
methyl and H3Ac (Merck Millipore, Burlington, MA, USA),
with rabbit immunoglobulin (Ig)G (Merck Millipore), used as
an isotype control. Chromatin was precipitated using A/G plus
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beads (Pierce™, Thermo Fisher Scientific), eluted and reverse
cross-linked using an overnight incubation with 4 M sodium
chloride (NaCl) at 65C. Following proteinase-K (Sigma)
digestion, DNA was precipitated using phenol-chloroform-
isoamyl alcohol and dissolved in nuclease-free water.
Quantitative real-time polymerase chain reaction (PCR)
was performed as 10 ml reactions in a 96-well optical
clear plate using 1 ml of precipitated DNA and custom
promoter-specific primers (Sigma; sequences obtained
from Xu et al.27) and SYBRPCR master mix (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA,
USA). The results were presented as the percent of input.
Ion ChIP-seq libraries were prepared from the ChIP DNA
using an Ion Plus Fragment Library Kit (Invitrogen, Thermo
Fisher Scientific, Waltham, MA, USA). Briefly, purified
ChIP DNA was end-repaired and purified with two rounds
of AMPure XP bead (Beckman Coulter, Brea, CA, USA)
capture to size-select fragments approximately 100–250 bp
in length. The end-repaired DNA was ligated to Ion-
compatible adapters. The library was amplified using PCR
with a limited number of cycles to generate sufficient mate-
rial for downstream template preparation. The final library
was between 170–220 bp in length. The purified, amplified
ChIP DNA library was diluted and an Ion OneTouch 200
Template Kit v2 DL (Invitrogen) was used to prepare
template-positive Ion OneTouch 200 Ion Sphere Particles
(ISPs) for 200 base-read sequencing of the ChIP DNA.
Template-positive ISPs were enriched using an Ion One-
Touch ES instrument and sequenced using an Ion PGM
200 Sequencing Kit (Invitrogen) and the Ion Torrent PGM
Instrument using Ion 316 chips (Thermo Fisher Scientific).
Data were analyzed using the Avadis NGS system (Banga-
lore, India). Sequencing data were validated using promoter-
specific primers (Sigma; sequences obtained from Xu
et al.27) as described above.
RNA Isolation, Poly(A)-Enrichment and
Transcriptome Sequencing
Organs were harvested, homogenized, dissolved in TRIzol
Reagent (Thermo Fisher Scientific) and RNA extracted fol-
lowing the manufacturer’s instructions. The Ambion Micro-
Poly(A)Purist™ kit (Ambion, Thermo Fisher Scientific) was
used to enrich the mRNA transcripts from the previously
isolated total RNA, which contains oligo(dT) cellulose to
isolate the poly(A) RNA fraction. The poly(A) RNA was
eluted using pre-warmed RNA storage solution, re-
precipitated and quantitated on Qubit (Thermo Fisher Scien-
tific). Ion RNA-Seq libraries were prepared from this poly-A
RNA using an Ion Total RNA-Seq Kit v2 (Invitrogen).
Briefly, the re-precipitated poly(A)-enriched RNA was frag-
mented using RNase III and purified using nucleic acid
binding beads. The purified, fragmented RNA was ligated
to Ion-compatible adaptors and subsequently amplified
using PCR with a limited number of cycles to generate suf-
ficient material for downstream template preparation. The
library was purified and analyzed using an Agilent 2100
Bioanalyzer instrument (Agilent Technologies, Mulgrave,
VIC, Australia). The purified, amplified poly(A)-enriched
library was diluted and an Ion OneTouch 200 Template Kit
v2 DL was used to prepare template-positive Ion OneTouch
200 Ion Sphere Particles (ISPs) for 200 base-read sequencing
of the enriched RNA. Template-positive ISPs were enriched
using an Ion OneTouch ES instrument and sequenced using
an Ion PGM 200 Sequencing Kit and the Ion Torrent PGM
Instrument using Ion 316 chips. Data were analyzed using
the Avadis NGS system (Bangalore, India).
Isolation of Human Adipose-Derived
Mesenchymal Cells
Human subcutaneous and visceral adipose tissues were
available as surgical excess following elective abdomino-
plasty at St Vincent’s Private Hospital (Melbourne, Austra-
lia). Cells were isolated from these tissues using a protocol
previously described by Zuk et al.28, with modifications.
Briefly, adipose tissue was mechanically minced into fine
pieces and cells were dissociated using an enzymatic diges-
tion (0.2% w/v) collagenase 1 for 60 min at 37C. Cells were
washed, centrifuged to remove adipocytes and pelleted cells
were cultured under standard conditions in low glucose
DMEM containing 5 mM glucose, 2 mM L-glutamine
(Sigma) and 100 U/ml antibiotic/antimycotic cocktail
(Gibco) at 37C in a humidified atmosphere containing 5%
CO2. Adherent populations were grown until they became
confluent under standard conditions, and sub-cultured at a
ratio of 1:2. The cultured populations of cells were termed
adipose-derived mesenchymal cells (AMCs).
Gene Expression Characterization Using
Quantitative PCR
Fresh adipose tissue from donor samples (Day 0) and AMCs
cultured to different passages were harvested in TRIzol and
RNA was extracted following the manufacturer’s instructions.
cDNA was prepared using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) and quantitative real-
time PCR of samples was performed in 96-well optical clear
plates using an Assay-on-Demand probe and primer mix
(Applied Biosystems; Supplementary Table 2) with TaqMan
Fast Universal PCR Master Mix, with 40 ng/100 ng DNA
inputs. PCR was performed using the ViiA7 Real-Time PCR
platform and data analyzed using Applied Biosystems ViiA7
Software. The results were normalized to housekeeping genes
(18 S). Data are presented as fold difference over the detect-
able Ct value, which was calculated using the DDCt method
(Ct value of 39 was considered to be undetectable)29.
Gene Expression Characterization Using In-situ PCR
Sub-cultured AMCs were characterized using an in-situ PCR
protocol previously described by Ranjan et al.30. Briefly,
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AMCs were sub-cultured onto eight-well chamber slides
(Thermo Fisher Scientific) and cultured to semi-
confluence. Cells were fixed in freshly prepared 4% paraf-
ormaldehyde (PFA; Sigma) and permeabilized using a
freeze–thaw technique. Cells were incubated with 20 ml
0.1 M ammonium chloride solution and in-situ cDNA was
prepared using a High Capacity cDNA Reverse Transcrip-
tion Kit. In-situ PCR was performed for 25 cycles using
Assay-on-Demand probe (Supplementary Table 2) and a
primer mix with TaqMan Fast Universal PCR Master Mix,
with independent reactions carried out in each well of the
eight-well chamber slide. Slides were fixed again in freshly
prepared 4% PFA and mounted in Vectashield mountant
(Vector Laboratories, Burlingame, CA, USA) containing
Hoechst 33342 (Invitrogen). Images were captured using a
Zeiss LSM 510 laser scanning microscope. Magnification,
laser power and detector gains were set below saturation and
were identical across samples.
Immunocytochemistry Characterization
Sub-cultured AMCs were characterized using an immuno-
cytochemistry protocol previously described by Joglekar
et al.26 Briefly, AMCs were sub-cultured onto eight-well
chamber slides (Thermo Fisher Scientific) and grown to con-
fluence. Cells were fixed in freshly prepared 4% PFA and
permeabilized using chilled 0.1% Triton X-100 (Sigma) for
30 min at room temperature. Cells were exposed to blocking
buffer composed of 4% normal donkey serum (NDS; Sigma)
for 30 min at room temperature. Primary antibodies were
diluted (1:100) in blocking buffer (4% NDS) and incubated
with cells overnight at 4C. Secondary antibodies were
diluted (1:200) in blocking buffer (4% NDS) and incubated
with cells for 1 h at 37C and mounted in Vectashield moun-
tant containing Hoechst 33342 (Sigma). Images were cap-
tured using a Zeiss LSM 510 laser scanning microscope.
Magnification, laser power and detector gains were set
below saturation and were identical across samples. Details
of primary and secondary antibodies used herein are pro-
vided in Supplementary Table 2.
Flow Cytometry Characterization
Sub-cultured AMCs were trypsinized into a single cell sus-
pension and maintained in serum-containing media at 37oC
for 60 min to allow the cells time to regenerate the surface
markers damaged or lost during the trypsinization. Non-
specific epitopes on cells were blocked using 4% NDS in
phosphate-buffered saline for 30 min at room temperature
followed by labeling cells in suspension with fluorescent-
conjugated primary antibodies at 4oC for 60 min in the dark.
Primary antibodies were purchased from BD Biosciences and
used at the concentrations indicated; anti-human CD29-PE
(1:100), CD34-FITC (1.5:100), CD45-FITC (2.5:100),
CD90-PE (1:200), CD31-FITC (1.5:100), CD44-PE (1:100),
CD73-FITC (1:100) and CD105-PE (1:100) with their
respective isotype controls (2.5:100). Cells were imaged on
a fluorescence-activated cell sorter Calibur (Becton Dickin-
son, Franklin Lakes, NJ, USA). Gating was implemented after
profiling unstained and isotype control cell samples.
Differentiation of Mouse AMCs Into an Endocrine
Pancreatic Lineage
Transgenic mice contained a green fluorescent protein (GFP)
reporter under the control of essential pancreatic promoters;
the pancreatic and duodenal homeobox 1 (Pdx1). Pdx1-GFP
mice were provided by Prof. Edouard Stanley and Prof.
Andrew Elefanty (MCRI, Melbourne, Australia) and were
maintained at our animal facility. Adipose-derived cells were
isolated and cultured using the protocol described above for
the isolation and culture of human cells. The differentiation
potential of mouse AMCs was confirmed using the protocol
described previously31–35. Mouse AMCs were sub-cultured as
a single cell suspension in serum-free media into low adhesion
tissue culture six-well plates, with each well containing 1 
106 cells. During differentiation, the expression of GFP was
visualized and imaged using the FLoid Cell Imaging Station
(ThermoFisher Scientific, Melbourne, VIC, Australia). Fur-
ther differentiation experiments were performed in black opa-
que 96-well flat bottom microplates for luminescence and
fluorescence assays. Differentiation assays used an amended
protocol to address the limitations of the small volumes and
well sizes used in the experiments. Adipose-derived cells
were sub-cultured into serum-free DMEM/F12 medium con-
taining 17.5 mM glucose, 1.0% (w/v) bovine serum albumin
and insulin-transferrin-selenium. GFP signals in each well
were quantitated using POLARstar OPTIMA (BMG Labtech
Pty Ltd, Mornington, VIC, Australia) multi-detection micro-
plate reader in real time. GFP intensity was used as an index
of promoter activity36. The level of fluorescence in the green
channel was automatically recorded and analyzed using
MARS Data Analysis software (BMG Labtech Pty Ltd, Mor-
nington, VIC, Australia) for each of the 96-wells in the micro-
plate. All values generated from these data were corrected
with respect to the blank (wells containing media but no cells)
and presented corrected to the fluorescence detected at day 1,
which were presented as ‘0’ fluorescence (this did not indicate
that no GFP expression was detected). This provided a stan-
dard against which changes in GFP intensity could be mea-
sured. The GFP intensity was therefore expected to diminish
further when exposed to an antagonist or to increase in inten-
sity when exposed to a known agonist of differentiation.
Transplantation of Adipose-Derived Islet-like
Cell Aggregates
TheraCytes™ (TheraCyte Inc, Laguna Hills, CA, USA) were
loaded with 300 to 500 islet-like cell aggregates (ICAs) dif-
ferentiated from human AMC cultures. The sealed
TheraCytes™ containing adipose-derived ICAs were trans-
planted in the peritoneal cavity and orientated such that they
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laid flush against the peritoneum above the left kidney in 12-
week-old male NOD/SCID mice, obtained from the Animal
Resource Centre (WA, Australia). Animals were made dia-
betic following a partial pancreatectomy procedure34,35 and
euthanized after 90 days and TheraCytes™ were retrieved.
The contents of the TheraCytes™ were scraped and collected
using fresh scalpel blades and solubilized in TRIzol Reagent.
RNA was extracted and cDNA was generated using the High
Capacity cDNA Reverse Transcription Kits. Quantitative
PCR characterization of samples was performed as 5 ml reac-
tions in a 96-well optical clear plate using 40 ng equivalent
of cDNA input and TaqMan Fast Universal PCR Master
Mix, as described previously. All values generated from
these data were represented as cycle threshold (Ct-) values
and presented as fold difference over the detectable Ct value,
which was calculated using the DDCt method (Ct value of 39
considered to be undetectable)29.
Human Insulin Enzyme-linked Immunosorbent Assay
Mice were administered 2 g/kg glucose at T¼0 and blood
samples were taken at 30 min. Insulin was measured in
serum following the centrifugation of blood samples using
a human ultra-sensitive insulin enzyme-linked immunosor-
bent assay (ELISA) kit (Mercodia, Uppsala, Sweden) and
values were normalized to the protein content.
Statistics
All data were obtained from at least three or more indepen-
dent experiments as stated in the methods and/or legends. A
two-way analysis of variance (ANOVA; ordinary with Fish-
er’s least significant difference test) or a one-way ANOVA
(ordinary with Holm–Sidak’s correction) were used for data
analysis using Prism (Sigma Software Distribution, Devon,
UK). Statistical significance was taken at p<0.05.
Results
Epigenetic and Transcriptomic Discovery Analyses
The chromatin structure of cells isolated from nine different
types of mouse tissue (pancreas, liver, stomach, subcuta-
neous fat depot, visceral fat depot, brain, heart, peritoneal
layer, and skin) was characterized using chromatin immuno-
precipitation (ChIP). Two distinct histone modifications at
the Pdx1 gene promoter region were examined (see methods
for details). Pancreatic tissue demonstrated the highest level
of open chromatin conformation for this master regulatory
endocrine pancreatic transcription factor as evidenced by a
higher level of H3K4 trimethylation as compared with H3K9
trimethylation (Fig. 1A, B). Interestingly, similar compari-
sons across other tissues indicated that the visceral fat depot
was very different from the subcutaneous fat depot and con-
tained cells that had a more ‘open’ conformation at the Pdx1
gene region. Most of the other tissues showed either very low
levels of open chromatin modifications (stomach,
subcutaneous fat, brain, skin) or showed significantly higher
levels of inactive mark (H3K9me3) at the Pdx1 gene promo-
ter region (e.g. liver, peritoneal layer; Fig. 1A, B). We then
assessed open chromatin conformation in visceral and pan-
creatic tissues using a ChIP-sequencing approach (Fig. 1C).
Indeed, the relative abundance of DNA that was pulled down
for this open chromatin modification (H3-acetylation) was
comparable between the pancreas and the visceral adipose
tissue for multiple endocrine genes including ins2, Pdx1,
mafB, gck, glut1, glut3 and insR. This inherent epigenetic
similarity with the pancreas suggested that cells derived
from visceral adipose tissue could represent a potential
source of endocrine progenitors.
The results of the sequencing study were validated
using real-time quantitative PCR on multiple samples for
H3K4 and H3K9 trimethylation as well as H3 acetylation
at selected regions of the Pdx1 gene and its promoter
(Fig. 2A–E). Due to its importance in pancreas develop-
ment and b-cell specification, five different primer pairs
targeting Pdx1 promoter and upstream elements27,
together with the gene promoter region for adiponectin
(Fig. 2F) were used. As depicted in Fig. 2, pancreatic
tissue samples showed an abundance of H3K4 trimethyla-
tion and H3 acetylation across all Pdx1 promoter regions,
as compared with the subcutaneous adipose tissue sam-
ples. Interestingly, visceral adipose tissue samples
showed a similar enrichment of methylation and acetyla-
tion signatures, especially in the upstream elements
(regions I through IV) of the Pdx1 gene promoter. These
data confirmed that the visceral adipose tissue samples
were enriched for histone post-translational modifications
that favor Pdx1 gene transcription. Collectively, these
data demonstrate the epigenetic similarities between the
pancreas and visceral adipose tissues, providing evidence
to support the assertion that visceral adipose tissue-
derived cells may contain an intrinsic capacity to differ-
entiate into Pdx1-expressing endocrine progenitor cells.
Gene expression analysis of pancreatic and adipose tissue
samples was achieved using RNA sequencing. The relative
transcript abundance of multiple genes is presented in Fig.
S1. Pancreatic tissue samples contained relatively higher
levels of transcripts for endocrine hormones (Ins1, Ins2,
Gcg), which were not detected in visceral adipose tissue
samples. Key pancreatic transcription factors in b-cell fate
determination; Pdx1, MafB, Gata6, as well as important
pancreatic function-related transcripts; glucokinase, glut1
and glut 2, were detected in both tissues, albeit at lower
levels in visceral adipose samples. The characteristic
mesenchymal intermediate filament vimentin (Vim) and adi-
pokines; leptin (Lep), adiponectin (Adipoq), resistin (Retn)
and visfatin (Nampt), were detected at significantly high
levels in adipose tissue samples relative to those detected
in the pancreas (Fig. S1). We therefore decided to further
study adipose tissue-derived cells as a potential source for
in-vitro differentiation to insulin-producing cells.
















































































































































































































































































































































































































































































































































































































































































































































Isolation and Characterization of Adipose Tissue-
derived Cells
Human visceral adipose-derived progenitor cells were cul-
tured as an adherent population of fibroblast-like cells.
These cells mostly exhibited a bipolar morphology. Owing
to their mesenchymal-like appearance in culture, we termed
this population as AMCs. Cultured AMCs were character-
ized with respect to a selected panel of mesenchymal-,
pluripotency-, adipose- and pancreas-associated genes at
periodic stages of culture, using TaqMan-based real-time
quantitative PCR (Fig. 3). Increased subculture was typically
Fig 2. Validation of ChIP sequencing using quantitative real-time PCR. Ct values for isotype (control), H3K4 trimethylation (me3), H3K9
trimethylation (me3) and H3 ac pulldown were normalized to input DNA and presented as percent of input for the Pdx1 promoter region
(A) as well as upstream regions I–IV (B–E) of the Pdx1 gene, which are recognized to be the pre-patterning modifications for pancreatic cell
fate (Xu et al.27). Adipose-specific epigenetic modifications were assessed at the adiponectin (Adipoq) gene promoter region. Data
presented as mean and SD from at least N¼5 or 6 tissues in each group. Shaded background regions indicate pancreatic (white backdrop),
subcutaneous adipose tissue (dark grey backdrop) and visceral adipose (light grey backdrop) tissue samples. Significant differences are
represented by a *(p<0.05) or **(p<0.01) as compared with the respective pancreatic tissue modification (K4, K9 or ac).
ChIP: chromatin immunoprecipitation; Ct: cycle threshold; PCR: polymerase chain reaction; SD: standard deviation.
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Fig 3. Gene expression characterization of cultured human AMCs. A comprehensive panel of genes were profiled for their expression in
visceral adipose tissue (day 0) and AMCs (passage 2/P2 through passage 10/P10 or more) generated from the same preparations. TaqMan-
based qPCR was performed and normalized to 18 s rRNA (housekeeping gene) and presented as fold difference over the detectable Ct limit
(Ct value of 39 was considered to be undetectable) using the DDCt method (Hardikar et al.29). Samples were characterized with respect to
selected panel of (A) mesenchymal-, (B) pluripotency-, (C) adipose- and (D) pancreas-associated genes at different stages of culture. Data are
generated from at least 3 to 5 different human preparations and presented as mean + SEM.
AMC: adipose tissue-derived mesenchymal cell; Ct: cycle threshold; qPCR: quantitative polymerase chain reaction; SEM: standard error of
the mean.
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associated with either increases or stable expression of
mesenchymal markers in culture (Fig. 3A). This data corro-
borates the visual observation of cultures achieving an
increasingly homogenous mesenchymal-like morphology
when cultured for multiple passages. Changes to the expres-
sion of pluripotency-associated genes in cultured cells were
inconsistent, with AMCs observed to be enriched for the
expression of certain genes (Myc, Smad2/3, Fgf2, Wnt3A)
while the expression of others was decreased (Fig. 3B). The
elevated expression of some of these markers was not indi-
cative of the population achieving a pluripotent phenotype
but rather suggested a much broader differentiation potential
(increased plasticity) with prolonged passaging. The expres-
sion of adipose or preadipocyte markers in AMCs offered
information regarding the retention of any adipose charac-
teristics of the source tissue and a measure of their propen-
sity to spontaneously differentiate into this phenotype (Fig.
3C). The expression of key adipokines (adiponectin and lep-
tin) decreased in abundance in the AMCs as compared with
the day 0 samples, whereas other adipose-associated tran-
scripts were typically expressed at consistent levels through-
out the culture.
AMCs were profiled for a panel of pancreas-associated
markers to investigate the expression of key endocrine
pancreatic transcripts during sub-culturing (Fig. 3D). Tran-
scripts encoding endocrine hormones (Ins, Gcg, and Sst)
were undetectable or expressed at very low levels in a
majority of AMC preparations. When transcription factors
essential to the pancreas and b-cell development were
assessed, we observed limited expression of Ngn3 and
MafA, while Pdx1 and Foxa1 expression increased follow-
ing 6 to 10 passages in vitro. Hes1, the negative regulator
of Ngn3, was seen to be enriched following prolonged in-
vitro expansion.
We carried out in-situ PCR using protocols optimized in
our lab30, to confirm the expression of adipose and pan-
creatic gene transcripts. Visfatin mRNA (positive control),
was observed to be almost ubiquitously expressed in cul-
tured cells (Fig. S2). The fluorescent signal (FAM) of
amplified visfatin mRNA was seen to be concentrated in
the perinuclear region, as is expected for most mRNAs.
Similarly, the fluorescent signal of amplified smooth mus-
cle actin mRNA was observed to be present in a majority of
cultured cells. However, the expression of MafA or Ngn3
was observed to be significantly limited, with only a small
fraction of the cells within AMC cultures expressing these
transcripts. These observations suggest that the AMCs con-
tained discrete sub-populations of MafA- and Ngn3-
expressing cells.
The cell surface antigens expressed by AMCs were quan-
tified using flow cytometry (Fig. 4A). AMCs represent a
fairly homogeneous population of mesenchymal-like cells
immunopositive for CD29 (95.2 + 1.4%), CD44 (96.2 +
4.4%), CD73 (97.8%), CD90 (98.4%) and CD105 (98.6 +
1.9%), and immunonegative for CD31 (0.8 + 0.3%), CD34
(0.7 + 0.4%) and CD45 (0.9 + 0.3%). Expression of leptin,
peroxisome proliferator-activated receptor gamma
(PPARg), and vimentin were assessed using immunocyto-
chemistry. Adipose-specific leptin and PPARg were pres-
ent only in few cells while vimentin was observed to be
ubiquitously expressed in cultured AMCs (Fig. 4B). The
stromal precursor antigen-1 (Stro-1), a potential biomarker
of multipotent progenitors37, was present in a majority of
AMCs indicating multilineage differentiation potential
(Fig. 4B).
Differentiation of AMCs into ICAs
The differentiation process was investigated using visceral
AMCs from a transgenic mouse model. These reporter mice
contained a GFP transgene under the control of the Pdx1
gene promoter38. AMCs isolated from this transgenic mouse
strain were analogous to equivalent cultures generated from
human adipose tissue (not shown). When exposed to serum-
free conditions31,32,34,35,39, AMCs formed ICAs that
expressed the GFP reporter, indicating Pdx1 promoter acti-
vation (Fig. 5A). The fluorescent signal generated by these
ICAs was quantitatively measured using the 96-well plate
reader, where GFP intensity was quantified over time as a
measure of endocrine pancreatic commitment. Differentia-
tion was induced in the presence of multiple growth and
differentiation factors at the concentrations indicated in Sup-
plementary Table 1, and the effect on Pdx1 promoter activity
was determined and presented in Fig. 5B. AMCs derived
from this transgenic animal failed to show a detectable
expression of GFP, indicating sub-optimal Pdx1 gene pro-
moter activity under standard culture conditions (Fig. 5C).
However, exposure to exendin-4 (Fig. 5D) and fibroblast
growth factor 2 (FGF2; Fig. 5E) increased the GFP signal
with time, reflecting increased promoter activity (Fig. 5B).
These data indicated that FGF2, as well as the exendin-4
agonist, promoted the differentiation of mouse AMCs into
the endocrine pancreatic lineage. Conversely, the antagonist
exendin-(9-39) was found to suppress GFP expression, indi-
cating decreased promoter activity and retardation of endo-
crine differentiation. Mouse AMC-derived ICAs were
harvested and analyzed using TaqMan-based real-time quan-
titative PCR. Undifferentiated monolayer cultures contained
undetectable endocrine transcripts, but differentiated ICAs
contained increased pancreatic transcripts, including Pdx1,
insulin 1, insulin 2 and somatostatin (Fig. 5F).
Transplantation Studies of Adipose-derived ICAs
We then adapted the differentiation conditions identified
using GFP-expressing mouse AMCs to differentiate human
visceral AMCs in vitro. Human AMC-derived ICAs were
transplanted into the abdominal cavity of NOD/SCID mice
using TheraCyte™ devices. These animals were subse-
quently rendered diabetic following partial pancreatectomy.
Grafts retrieved 90 days post-transplantation showed a sig-
nificant increase in pro-insulin gene transcripts (Fig. 5G).
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The transcripts for the glucose transporters Glut1 and Glut2
were increased compared with day 0 samples, which is par-
ticularly interesting given that Glut1 expression is signifi-
cantly higher in human b-cells. Pdx1, Ngn3, and MafA
expression were also elevated by around 10- to 100-fold,
as compared with their day 0 levels. Analysis of the retrieved
graft from TheraCyte™ devices demonstrated efficient vas-
cularization (Fig. 5 H). Blood samples collected from per-
ipheral circulation of these mice following a glucose
injection (30 minutes before retrieval) showed that differen-
tiated and engrafted human AMC-derived ICAs could
secrete detectable levels of insulin in response to a glucose
stimulus (Fig. 5I) and contained insulin-immunopositive
cells (Fig. 5J, red).
Discussion
Any study involving the conversion of stem or progenitor
cells to an insulin-producing phenotype involves overwriting
and reprogramming elements of a profoundly complex and
carefully orchestrated biological system. The discovery
study presented in this manuscript was initiated to under-
stand the histone modifications at the pro-pancreatic gene
promoter region, in cells derived from multiple tissues. This
unbiased approach provided the opportunity to examine and
characterize the epigenome of a wide variety of potential cell
populations, and to provide information regarding their dif-
ferentiation potential into an endocrine pancreatic lineage.
The similarities identified at representative promoter regions
Fig 4. Surface and intracellular antigen profile of human AMCs. Human AMCs were characterized using flow cytometry (A) for the
expression of different mesenchymal and hematopoietic surface antigens. Isotype controls are shown in red, while the specific antibody
that was used is in blue; N¼4/group. (B) AMCs exhibit presence of adipose markers (leptin and PPARg) in fewer cells and are more
homogeneous for the expression of the mesenchymal marker; vimentin and the pluripotency marker Stro1. Nuclei are stained with Hoechst
and are presented here in red or blue, while other antigens are shown in green or red as indicated. Images were obtained using LSM 510
Meta confocal microscope on an Axio Observer Z1 platform. Laser intensities, gains and offsets were maintained similar, and below
saturation levels for each scan. Bar represents 20 mm.
AMC: adipose tissue-derived mesenchymal cell; PPARg: peroxisome proliferator-activated receptor gamma.
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Fig 5. Differentiation and function of AMCs. (A) Visceral adipose-derived AMCs from Pdx1-GFP mice were exposed to various growth and
differentiation factors. Panel (A) represents the experimental setup where GFP reporter (Pdx1-GFP) AMCs were plated in (black) 96-well
plates and fluorescent intensities recorded as detailed in methods. Note that some (minimal) level of GFP seen in the cells (wells 1 and 2),
represented as ‘0’ intensity, diminished when exposed to the GLP1 antagonist (exendin 9-39; wells 3 and 4) or to increase in intensity when
exposed to an agonist (wells 5 and 6). All conditions were set up in triplicate. (B) Cultures were stimulated to differentiate in the presence of
the small molecules described in Supplementary Table 2 and the intensity of GFP fluorescence was measured at the same time of the day and
at regular (24 h) intervals. Data were corrected with respect to the blank (well containing media but no cells) and presented relative to the
GFP signal measured on day 1. Values generated for day 1 are therefore presented as ‘0’ fluorescence, while subsequent measurements are
presented relative to day 1. AMCs generated from Pdx1-GFP transgenic mice do not show GFP expression as monolayers (C). However,
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of genes relevant to the b-cell development and insulin
expression provided evidence of an underlying predisposi-
tion of visceral adipose-derived cells to differentiate into an
endocrine pancreatic lineage. As we summarized earlier40,
populations of lineage-committed cells represent a source
that would predictably require fewer manipulations, to
achieve differentiation into the desired endocrine pancreatic
phenotype. We theorized that cells derived from a tissue that
already exhibited several key epigenetic traits similar to a
pancreatic b-cell would represent a viable candidate popu-
lation for differentiation studies.
We characterized and compared the abundance of differ-
ent histone modifications that confer an ‘open’ or active
chromatin conformation in different tissues using ChIP-seq
analysis followed by validation using real-time quantitative
PCR. Analysis of immunoprecipitated DNA from visceral
adipose tissue demonstrated an epigenetic signature
(H3K4me3, H3K9me3, and H3Ac) at islet-specific gene pro-
moters, similar to those in the pancreas. However, this did
not imply that these similarities manifest at the transcrip-
tome level. Subsequent transcriptome analysis demonstrated
distinct differences in the mRNA profiles of the respective
tissues, as expected for two developmentally distinct tissues
with such separate functional and histological phenotypes.
Nonetheless, the epigenetic similarities between adipose and
pancreatic tissues demanded further investigation into the
understanding the differentiation potential of visceral
adipose-derived cells.
We generated a fibroblast-like cell population from adi-
pose tissue and referred to them as AMCs. Early passage
(P0–P2) AMCs did not represent a uniform population of
cells, however, following further in-vitro culture, these
AMCs tended to become more homogeneous and exhibit a
characteristic mesenchymal phenotype, indicating a shift in
cell composition during culture41. AMCs demonstrated an
increasing abundance of mesenchymal (vim, fn1, snai1,
CD44, ItgaV) as well as pluripotency (myc, smad2/3, fgf2,
wnt3A) markers during in-vitro culture (Fig. 3A, B). The
abundance of adipogenic or preadipocyte transcripts (Adi-
poq, cfd, Lep, Adrb1) progressively decreased during P0–
P10 while pancreatic or pro-endocrine gene transcripts
(insR, Ngn3, FoxA1, Pdx1) increased during this time
(Fig. 3C, D). Although this gene expression profile indicates
a pancreatic lineage prone precursor population, passaging
of AMCs was also associated with progressive increases in
the abundance of Hes1; a negative regulator of the pro-
endocrine gene Ngn3. Since such gene expression data rep-
resent population analysis, which averages the variation
amongst the millions of single cells in a population, we used
in-situ PCR to capture low copy number transcripts in AMC
cultures. Using in-situ PCR established in our lab30, we
observed that a small subset of AMCs contain pancreas-
specific transcripts in high abundance. However, despite the
inherent heterogeneity observed in cells derived from adi-
pose tissue, the propensity to differentiate into an endocrine
pancreatic lineage is detected in our initial discovery and
cultured cell characterization studies.
We used transgenic AMCs isolated from Pdx1-GFP
mice to provide real-time monitoring of GFP intensity as
an index of differentiation to endocrine pancreatic line-
age36. The differentiation process was adapted from a pro-
tocol used in our lab for the differentiation of human
pancreatic precursor cells to an endocrine pancreas
lineage31,32,34,35,39. Cultured AMCs did not express the
reporter due to inactivity of the conjugate Pdx1 promoter
(Fig. 5C). However, when stimulated to differentiate, pro-
moter activity increases in response to the differentiation
process, which is reflected by an increase in GFP expres-
sion proportional to promoter activity (Fig. 5B, D, E). This
technique provided a means to measure promoter activity in
real time, to extrapolate gene transcription under different
conditions. By quantifying the intensity of the GFP reporter
signal at regular intervals, the activity of the associated
promoter was measured and the commitment to a specific
phenotype inferred. Increasing expression of the GFP
reporter in differentiating AMCs generated from Pdx1-
GFP animals indicated that they had achieved a state of
commitment to an endocrine pancreatic lineage.
Cultured transgenic cells were stimulated to differentiate
when treated with a variety of small molecules intended to
promote the differentiation of mouse AMCs into an endo-
crine pancreatic lineage. These agents were specifically cho-
sen for their documented effects on chromatin structure,
differentiation and pancreas biology (see references 56–63
Fig 5. (Continued). when stimulated to differentiate into an endocrine pancreatic lineage, AMCs formed multiple, small ICAs that express
GFP in presence of exendin-4 (D) or FGF2 (E). Bar ¼ 20mm. GFP-expressing ICAs were analyzed using TaqMan-based quantitative PCR for
the expression of endocrine pancreatic gene transcripts. Data are presented as fold difference over the detectable Ct value was calculated
using the DDCt method (Hardikar A et al.29) (F). Human AMCs were induced to differentiate into endocrine pancreatic lineage using FGF2
and exendin-4 agonist and transplanted in NOD/SCID mice using TheraCyte™ devices. Human AMC-derived ICAs showed detectable
expression of pro-endocrine gene transcripts (G). Box and whisker plot showing the abundance of transcript at day 90 relative to expression
in day 0 (undifferentiated) AMCs. The line in the box represents the median and the box represents the upper and lower quartile (N¼4
mice). ICA-containing TheraCytes™ showed evidence of vascularization (H), showed detectable levels of human insulin (mean + SD; N¼3)
in mouse circulation (I) and contained insulin-producing cells after 90 days of in-vivo studies (J); red: insulin, blue: DAPI: nuclei; bar ¼ 20mm.
AMC: adipose tissue-derived mesenchymal cell; ICA: islet-like cell aggregate; AMC: Adipose-derived mesenchymal cells; ICAs: Islet-like Cell
Aggregates; Pdx1: Pancreatic and duodenal homeobox 1; GLP1: Glucagon-like Peptide 1; GFP: Green Fluoroscence Protein; FGF2: Fibro-
blast Growth Factor 2; PCR: Polymerase Chain Reaction; Ct: Cycle threshold; NOD/SCID: Non-obese Diabetic/Severe Combined Immu-
nodeficiency; DAPI: 40,6-diamidino-2-phenylindole; SD: Standard Deviation.
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in Supplementary Table 1). We observed enhanced GFP
expression in the presence of FGF2 and exendin-4. FGF2
is involved in many biological processes including angio-
genesis, embryonic development, and wound healing. It has
been shown to promote the differentiation of adipose-
derived cells42 and loss of FGF signaling has been impli-
cated in b-cell loss and the development of diabetes43.
We31,44 and others45,46 have also demonstrated a role of
FGF2 in the early stages of endocrine pancreas differentia-
tion. Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor
agonist promotes the differentiation of pancreatic progenitor
populations (such as ductal progenitor cells) and increases
proliferation and maturation in b-cells during develop-
ment47,48. Exendin-(9-39), a truncated version of exendin-4
that acts as a competitive antagonist at the GLP-1 recep-
tor49,50, was chosen as a negative control and was seen to
suppress differentiation (Fig. 5B).
Animal studies were carried out using the TheraCyte™
devices for transplantation. TheraCyte™ devices were used
to facilitate easy and clean retrieval of human AMCs follow-
ing transplantation. After optimal engraftment (determined
as 2 weeks post-transplant, through previous studies from
our lab34,35), these mice underwent partial pancreatectomy
to remove the distal portion of the pancreas, rendering them
surgically diabetic. This protocol38 is well described by our
lab and has been shown to promote the differentiation of
transplanted cells potentially through the paracrine factors
released from the regenerating pancreas28,30. The results of
the transplantation studies suggested that transplanted cells
continued to mature and differentiate following surgery. Tis-
sue grafts were recovered after 90 days and profiled for
major pancreatic hormones, transcription factors and recep-
tors using quantitative PCR. Analysis of the circulating
human insulin concentrations in mouse plasma of trans-
planted animals demonstrated that the transplanted cells
were capable of producing and secreting insulin (Fig. 5I,
J). These studies confirmed that AMCs could not only dif-
ferentiate to an endocrine pancreatic lineage in vitro but
potentially act as a source of insulin for treatment of diabetes
in vivo.
Over the past several years, we have assessed the poten-
tial of multiple human stem/progenitor cells including those
from pancreatic ducts, bone marrow and umbilical cord
blood-derived mononuclear cells. In order to assess differ-
entiation efficiency of human AMCs, we compared the lev-
els of insulin transcripts following differentiation of various
biological replicates (and different passages) of the above
stem/progenitor cell types. Intriguingly, differentiated
human AMCs contained a significantly higher number of
insulin transcripts than any of the other stem/progenitor cells
tested in our lab (Fig. S3), although these were all signifi-
cantly lower as compared with insulin transcripts detected in
human islets. The present study therefore has merits in iden-
tification of a cell type (visceral AMCs) and a protocol
(based on mouse AMC Pdx1 expression) for efficient differ-
entiation of progenitor cells. As compared with several other
therapies, such as those involving islet transplantation, the
major advantage is that the source of AMCs can be autolo-
gous and potentially more abundant.
Strengths and Limitations of This Study
The study strengths are (1) a genome-wide epigenetic and
transcriptomic profiling of multiple mouse tissues; and (2)
identification of visceral, but not subcutaneous adipose tis-
sue as a preferred source of progenitor cells with the poten-
tial to differentiate into an endocrine pancreatic cell lineage.
Characterization of AMCs demonstrates that these could be
expanded and differentiated into an endocrine pancreatic
lineage in vitro and that they would continue to differentiate
and produce human insulin in vivo. These cells appear to
retain their differentiated characteristics in vivo, indicating
that this cell population may prove to be an important can-
didate for cell replacement therapy in diabetes.
One of the study limitations is the depth of sequencing. We
employed an Ion Torrent PGM platform for ChIP-seq and
RNA-seq studies using a 316 chip that can provide up to 3
million clean reads. Although multiple samples were pooled
from different sequencing runs, the overall low sequencing
depth indicates that some of the lower abundance transcripts
or DNA species may not have been captured into the repre-
sentative libraries that we screened. However, it is intriguing
to note that in spite of this low depth, several of the pancreatic
pro-endocrine genes were seen to be accessible for transcrip-
tion (Fig. 1C) and that several of these genes were also tran-
scribed (Supplementary Fig. 1) in visceral adipose tissue.
These observations present the first evidence that pro-
endocrine gene transcripts are expressed in a subset of AMCs.
Another potential limitation is the applicability of in-vitro
differentiation protocols optimized in mice, to the differen-
tiation of human AMCs. Even though the broader functions
of human and mouse tissues are similar, they can differ from
each other in aspects including tissue architecture51,52,
response to different enzymes53, cytokines and pathway acti-
vation54,55 and islet cell proliferation39. We identified a pro-
tocol that facilitates maximal activation of the mouse Pdx1
reporter gene during differentiation of mouse AMCs (Fig.
5B). While this knowledge generated from the in-vitro
mouse AMC reporter system, may or may not be the most
efficient protocol to differentiate human AMCs to insulin-
producing cells, these studies provide us with a starting point
to test the differentiation potential of human AMCs. Further
studies to explore these possibilities are merited.
The current study opens up several avenues for future
exploration. Although pluripotency and pro-pancreatic gene
transcripts increased in abundance with progressive passa-
ging, Hes1 expression increased concomitantly. Strategies
targeting Hes1 repression, either through site-directed muta-
genesis or by inhibition of Hes1 via regulatory RNAs or
small molecules may facilitate the differentiation of this
easily derivable as well as highly abundant source of pan-
creatic progenitor cells.
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